Regional and subtype-specific mutational patterns of HIV-1 transmitted drug resistance (TDR) are essential for informing first-line antiretroviral (ARV) therapy guidelines and designing diagnostic assays for use in regions where standard genotypic resistance testing is not affordable. We sought to understand the molecular epidemiology of TDR and to identify the HIV-1 drug-resistance mutations responsible for TDR in different regions and virus subtypes.status: publishe
Human immunodeficiency virus type 1 (HIV-1) exhibits extraordinary genetic diversity that is driven ...
The latest NNRTI rilpivirine is indicated for HIV-1 patients initiating antiretroviral treatment, bu...
Abstract: Background: The introduction of the highly active antiretroviral therapy in the mid-1990s ...
Regional and subtype-specific mutational patterns of HIV-1 transmitted drug resistance (TDR) are ess...
Background Regional and subtype-specific mutational patterns of HIV-1 transmitted drug resistance (T...
PMID: 25849352 WOS:000354825700001Regional and subtype-specific mutational patterns of HIV-1 transmi...
Regional and subtype-specific mutational patterns of HIV-1 transmitted drug resistance (TDR) are ess...
Up until 10 years ago, basic and clinical HIV-1 research was mainly performed on HIV-1 subtype B tha...
Programs that monitor local, national, and regional levels of transmitted HIV-1 drug resistance info...
Objectives: To examine factors influencing the rate of transmitted drug resistance (TDR) among seroc...
Objectives: To determine the contribution of transmission clusters to transmitted drug resistance (T...
To determine the impact of transmitted drug resistance (TDR) of HIV-1 on treatment outcome in areas ...
Transmitted drug resistance (TDR) is a clinical and epidemiological problem because it may contribut...
Human immunodeficiency virus type 1 (HIV-1) genomes often carry one or more mutations associated wit...
OBJECTIVES: To examine factors influencing the rate of transmitted drug resistance (TDR) among seroc...
Human immunodeficiency virus type 1 (HIV-1) exhibits extraordinary genetic diversity that is driven ...
The latest NNRTI rilpivirine is indicated for HIV-1 patients initiating antiretroviral treatment, bu...
Abstract: Background: The introduction of the highly active antiretroviral therapy in the mid-1990s ...
Regional and subtype-specific mutational patterns of HIV-1 transmitted drug resistance (TDR) are ess...
Background Regional and subtype-specific mutational patterns of HIV-1 transmitted drug resistance (T...
PMID: 25849352 WOS:000354825700001Regional and subtype-specific mutational patterns of HIV-1 transmi...
Regional and subtype-specific mutational patterns of HIV-1 transmitted drug resistance (TDR) are ess...
Up until 10 years ago, basic and clinical HIV-1 research was mainly performed on HIV-1 subtype B tha...
Programs that monitor local, national, and regional levels of transmitted HIV-1 drug resistance info...
Objectives: To examine factors influencing the rate of transmitted drug resistance (TDR) among seroc...
Objectives: To determine the contribution of transmission clusters to transmitted drug resistance (T...
To determine the impact of transmitted drug resistance (TDR) of HIV-1 on treatment outcome in areas ...
Transmitted drug resistance (TDR) is a clinical and epidemiological problem because it may contribut...
Human immunodeficiency virus type 1 (HIV-1) genomes often carry one or more mutations associated wit...
OBJECTIVES: To examine factors influencing the rate of transmitted drug resistance (TDR) among seroc...
Human immunodeficiency virus type 1 (HIV-1) exhibits extraordinary genetic diversity that is driven ...
The latest NNRTI rilpivirine is indicated for HIV-1 patients initiating antiretroviral treatment, bu...
Abstract: Background: The introduction of the highly active antiretroviral therapy in the mid-1990s ...